ReviewMolecular diagnosis & therapy2008
Gastrointestinal stromal tumors: key to diagnosis and choice of therapy.
Review in Molecular diagnosis & therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Endoscopic ultrasound-guided cutting of holes and deep biopsy for diagnosis of gastric infiltrative tumors and gastrointestinal submucosal tumors using a novel vertical diathermic loop.World journal of gastroenterology · 2017Trial
- Clinical characteristics and prognostic indicators for metastatic melanoma: data from 446 patients in north China.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Neoadjuvant imatinib: longer the better, need to modify risk stratification for adjuvant imatinib.Journal of gastrointestinal oncology · 2016Article
- Role of surgery in patients with focally progressive gastrointestinal stromal tumors resistant to imatinib.Scientific reports · 2016Article
- Genomic mapping of pathways in endometrial adenocarcinoma and a gastrointestinal stromal tumor located in Meckel's diverticulum.Oncology letters · 2016Article
- Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor.Clinics (Sao Paulo, Brazil) · 2014Article
- Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience.Oncology letters · 2013Article
- Extended adjuvant therapy with imatinib in patients with gastrointestinal stromal tumors : recommendations for patient selection, risk assessment, and molecular response monitoring.Molecular diagnosis & therapy · 2013Article
- Article
- Characteristics of computed tomography imaging of gastrointestinal stromal tumor (GIST) and related diagnostic problems.Polish journal of radiology · 2011Article
- Functional features of gene expression profiles differentiating gastrointestinal stromal tumours according to KIT mutations and expression.BMC cancer · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The common feature of gastrointestinal stromal tumors (GISTs) is the expression of KIT protein or acquisition of activating, constitutive mutations in the KIT or platelet-derived growth factor receptor alpha (PDGFRA) genes that are the early oncogenic events during GIST development. With these discoveries, GIST has emerged as a distinct sarcoma entity, enabling the introduction of targeted therapy using the inhibition of KIT/PDGFRA and their downstream signaling cascade. The introduction of a small-molecule tyrosine kinase inhibitor, imatinib mesylate, to clinical practice has revolutionized the treatment of patients with advanced GISTs and is currently approved as first-line treatment for patients with metastatic and/or inoperable GISTs. Mutation screening is currently a tool in GIST diagnosis, assessment of sensitivity to tyrosine kinase inhibitors, and prediction of achieving response to molecularly targeted therapy. This article discusses the histologic and molecular criteria for distinguishing GISTs from other types of sarcoma, and the molecular diagnostic tools that are currently available or in development to assist in therapy decisions.
Indexed as
Identifiers
18510377What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.